[go: up one dir, main page]

MX2023007840A - Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo. - Google Patents

Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo.

Info

Publication number
MX2023007840A
MX2023007840A MX2023007840A MX2023007840A MX2023007840A MX 2023007840 A MX2023007840 A MX 2023007840A MX 2023007840 A MX2023007840 A MX 2023007840A MX 2023007840 A MX2023007840 A MX 2023007840A MX 2023007840 A MX2023007840 A MX 2023007840A
Authority
MX
Mexico
Prior art keywords
antibody fragments
monovalent anti
antibodies
properdin antibodies
properdin
Prior art date
Application number
MX2023007840A
Other languages
English (en)
Inventor
Paul P Tamburini
Douglas L Sheridan
Taneisha Ann- Tanara Mack
Walter C Voegtli
Original Assignee
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharma Inc filed Critical Alexion Pharma Inc
Publication of MX2023007840A publication Critical patent/MX2023007840A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se describen en la presente anticuerpos monovalentes aislados o fragmentos de anticuerpo del mismo que se unen a properdina humana. Esos anticuerpos son usados en un método de tratamiento para enfermedades mediadas por desregulación de la vía alternativa del complemento.
MX2023007840A 2017-01-30 2019-07-25 Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo. MX2023007840A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762452187P 2017-01-30 2017-01-30

Publications (1)

Publication Number Publication Date
MX2023007840A true MX2023007840A (es) 2023-07-07

Family

ID=62978808

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2019008827A MX2019008827A (es) 2017-01-30 2018-01-30 Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo.
MX2023007840A MX2023007840A (es) 2017-01-30 2019-07-25 Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo.
MX2023004333A MX2023004333A (es) 2017-01-30 2019-07-25 Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019008827A MX2019008827A (es) 2017-01-30 2018-01-30 Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023004333A MX2023004333A (es) 2017-01-30 2019-07-25 Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo.

Country Status (12)

Country Link
US (2) US11198725B2 (es)
EP (1) EP3573661A4 (es)
JP (3) JP7101684B2 (es)
KR (2) KR20230173731A (es)
CN (2) CN110831626B (es)
AU (2) AU2018212012B2 (es)
BR (1) BR112019014652A2 (es)
CA (1) CA3049806A1 (es)
CO (1) CO2019007686A2 (es)
IL (2) IL267898B2 (es)
MX (3) MX2019008827A (es)
WO (1) WO2018140956A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL267898B2 (en) * 2017-01-30 2024-06-01 Alexion Pharma Inc Monovalent antibodies against properdin and their fragments
IL271920B2 (en) 2017-07-11 2024-03-01 Alexion Pharma Inc Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof
CN112969367B (zh) * 2018-09-13 2023-04-07 瑞泽恩制药公司 作为c3肾小球病模型的补体因子h基因敲除大鼠
EP4087869A4 (en) * 2020-01-08 2024-03-06 Zydus Lifesciences Limited Anti-properdin antibodies and preparation thereof
US20250171423A1 (en) 2020-09-23 2025-05-29 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement mediated disorders
CN114432449B (zh) * 2020-10-30 2024-05-28 广州市妇女儿童医疗中心 用于抑制mhc-i和/或ii信号通路的试剂在治疗胆道闭锁中的应用
WO2023023227A1 (en) 2021-08-20 2023-02-23 Alexion Pharmaceuticals, Inc. Methods for treating sickle cell disease or beta thalassemia using complement alternative pathway inhibitors
US11981727B2 (en) 2021-08-31 2024-05-14 Novelmed Therapeutics, Inc Monospecific and bispecific antibodies and antigen binding fragments thereof
WO2024108529A1 (en) * 2022-11-25 2024-05-30 Linno Pharmaceuticals Inc. Properdin binding protein and use thereof
TW202413435A (zh) * 2022-08-05 2024-04-01 美商艾力克森製藥公司 融合蛋白的藥物組成物及其使用方法
CA3266365A1 (en) * 2022-08-31 2024-03-07 Alexion Pharmaceuticals, Inc. DOSAGE AND ADMINISTRATION OF FUSION POLYPEPTIDES FOR THE TREATMENT OF SICKLE CELL DISEASE
JP2025538611A (ja) 2022-11-25 2025-11-28 リンノ ファーマシューティカルズ インコーポレイテッド プロパージン結合タンパク質およびその使用
CN120399074B (zh) * 2023-06-02 2025-12-30 安徽金百奥生物科技有限公司 一种与人dr3胞外域高亲和力的纳米抗体

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2857516T3 (en) 2000-04-11 2017-08-07 Genentech Inc Multivalent antibodies and uses thereof
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
RU2007132188A (ru) 2005-01-25 2009-03-10 Селл Терапьютикс, Инк. (Us) Конъюгаты биологически активных белков, имеющие модифицированное время полужизни in vivo
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
MX337061B (es) * 2005-11-04 2016-02-11 Genentech Inc Uso de inhibidores de la via del complemento para tratar enfermedades oculares.
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
WO2011112850A2 (en) 2010-03-10 2011-09-15 Novelmed Therapeutics, Inc. Humanized and chimeric anti-properdin antibodies
EP2262831B1 (en) * 2008-03-03 2015-01-21 NovelMed Therapeutics, Inc. Anti-properdin antibodies
JP2012531418A (ja) 2009-06-23 2012-12-10 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体タンパク質に結合する二重特異性抗体
UY32920A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moleculas de unión biespecíficas para la terapia anti-angiogénesis
JP6174489B2 (ja) 2010-09-28 2017-08-02 アエゲリオン ファーマシューティカルズ，インコーポレイテッド 高可溶性レプチン
CU24111B1 (es) 2010-11-08 2015-08-27 Novartis Ag Polipéptidos que se enlazan a cxcr2
KR20140064768A (ko) 2011-07-01 2014-05-28 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 항-프로퍼딘 항체 및 그의 용도
US9382304B2 (en) * 2011-07-08 2016-07-05 Amylin Pharmaceuticals, Llc Engineered polypeptides having enhanced duration of action with reduced immunogenicity
SG10201703249PA (en) 2011-12-21 2017-05-30 Novartis Ag Compositions and methods for antibodies targeting factor p
AU2012362217A1 (en) 2011-12-28 2014-07-24 Novelmed Therapeutics, Inc. Aglycosylated human antibody and fusion protein and uses thereof
EP2904014A4 (en) 2012-10-04 2016-09-28 Novelmed Therapeutics Inc FOR ALTERNATIVE PATHS, SPECIFIC ANTIBODIES FOR THE TREATMENT OF HEMOLYTIC DISEASES
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
IL267898B2 (en) * 2017-01-30 2024-06-01 Alexion Pharma Inc Monovalent antibodies against properdin and their fragments
CN110003335B (zh) * 2019-04-12 2023-07-04 深圳普瑞金生物药业股份有限公司 Cd47单域抗体、核酸及试剂盒

Also Published As

Publication number Publication date
KR20190111946A (ko) 2019-10-02
US11198725B2 (en) 2021-12-14
IL267898A (en) 2019-09-26
JP7101684B2 (ja) 2022-07-15
EP3573661A4 (en) 2020-08-12
IL267898B1 (en) 2024-02-01
AU2018212012B2 (en) 2025-02-13
KR20230173731A (ko) 2023-12-27
MX2023004333A (es) 2023-05-04
AU2018212012A1 (en) 2019-07-25
CA3049806A1 (en) 2018-08-02
JP2022153405A (ja) 2022-10-12
JP2020507561A (ja) 2020-03-12
RU2019124873A3 (es) 2021-03-01
RU2019124873A (ru) 2021-03-01
CO2019007686A2 (es) 2019-07-31
US20220162292A1 (en) 2022-05-26
IL267898B2 (en) 2024-06-01
MX2019008827A (es) 2019-09-26
IL309890A (en) 2024-03-01
EP3573661A1 (en) 2019-12-04
BR112019014652A2 (pt) 2020-08-18
CN110831626B (zh) 2024-04-19
JP2024116321A (ja) 2024-08-27
CN110831626A (zh) 2020-02-21
US12497445B2 (en) 2025-12-16
CN118184777A (zh) 2024-06-14
KR102613874B1 (ko) 2023-12-15
US20190352381A1 (en) 2019-11-21
WO2018140956A1 (en) 2018-08-02
AU2025200709A1 (en) 2025-02-20

Similar Documents

Publication Publication Date Title
MX2023007840A (es) Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo.
PH12019500923A1 (en) Anti-pd-1 antibodies and compositions
ZA201901924B (en) Anti¿lag¿3 antibodies and compositions
MX2022004072A (es) Anticuerpos de factor xi y metodos de uso.
ZA201801852B (en) Anti¿pd¿1 antibodies and compositions
ZA201708265B (en) Tigit-binding agents and uses thereof
NZ758301A (en) Anti-trem2 antibodies and methods of use thereof
EA201792221A1 (ru) Антитела против сортилина и способы их применения
MX2022005253A (es) Anticuerpos neutralizantes de poliomavirus.
GEP20227343B (en) Anti-lag3 antibodies and antigen-binding fragments
PH12018500663A1 (en) Antigen-binding proteins that activate the leptin receptor
MX2022008523A (es) Compuestos que interactuan con glicanos y metodos de uso.
PH12017501522A1 (en) Antibodies to tau and uses thereof
JOP20190093A1 (ar) أجسام مضادة لـ il-33 واستخداماتها
EP4603508A3 (en) Anti-frizzled antibodies and methods of use
MX2020008122A (es) Anticuerpos anti-pd-1.
PH12017502020A1 (en) Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
NZ626242A (en) Anti-asic1 antibodies and uses thereof
MX2019009498A (es) Anticuerpos mimeticos de fgf21 y usos de los mismos.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
PH12019500342A1 (en) Antibody or an antigen-binding fragment thereof capable of binding to a human receptor of interleukin-6
MA40536A (fr) Anticorps anti-alpha v bêta 5 humanisés et leurs utilisations
PH12022550671A1 (en) Antigen binding proteins
JOP20190101A1 (ar) أنظمة علاج
MX2020013243A (es) Anticuerpos anti-il-22, fragmentos de anticuerpo, sus inmunoconjugados y usos de los mismos.